Glucagon-like peptide 2: A new treatment for chemotherapy-induced enteriris

Journal of Surgical Research

Volumn 91, Issue 1, 2000, Pages 77-82

  Tavakkolizadeh, A ^a,b   Shen, R ^a,b   Abraham, P ^a   Kormi, N ^a   Seifert, P ^c   Edelman, E R ^c   Jacobs, D O ^a,b   Zinner, M J ^a,b   Ashley, S W ^a,b   Whang, E E ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

5 fluorouracil; Chemotherapy; Glucagon like peptide 2; Intestine

Indexed keywords

BROXURIDINE; FLUOROURACIL; GLUCAGON LIKE PEPTIDE; TEDUGLUTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; DIGESTIVE SYSTEM CANCER; DRUG EFFECT; ENTERITIS; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0034212591     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.2000.5917     Document Type: Article

References (33)

1. Mamounas E., Wieand S., Wolmark N., Bear H. D., Atkins J. N., Song K., Jones J., Rockette H. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) [see comments]. J. Clin. Oncol. 17:1999;1349.
2. Lancet. 345:1995;939.
3. Petrelli N., Herrera L., Rustum Y., Burke P., Creaven P., Stulc J., Emrich L., Mittelman A. A prospective trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J. Clin. Oncol. 5:1987;1559.
4. Hartmann K., Heidelberg C. Studies on fluorinated pyrimidine. XIII. Inhibition of thymidylate synthase. J. Biol. Chem. 236:1961;3006.
5. Glazer R., Lloyd L. Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture. Mol. Pharmacol. 21:1982;468.
6. Ansfield F., Klotz J., Nealon T., Ramirez G., Minton J., Hill G., Wilson W., Davis H., Cornell G. A phase III study comparing the clinical utility of four regimens of 5-fluorouracil. Cancer. 39:1977;34.
7. Oster G. Hospitalization for 5-FU toxicity in metastatic colorectal cancer: Incidence and cost. Oncology (Huntingt.). 13:1999;41.
8. Cascinu S., Fedeli A., Fedeli S. L., Catalano G. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: A randomized trial. J. Clin. Oncol. 11:1993;148.
9. Decker-Baumann C., Buhl K., Frohmuller S., von Herbay A., Dueck M., Schlag P. M. Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer. Eur. J. Cancer. 35:1999;202.
10. Wadler S., Benson A. B. 3rd, Engelking C., Catalano R., Field M., Kornblau S. M., Mitchell E., Rubin J., Trotta P., Vokes E. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J. Clin. Oncol. 16:1998;3169.
11. Tsai C. H., Hill M., Asa S. L., Brubaker P. L., Drucker D. J. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am. J. Physiol. 273:1997;E77.
12. Brubaker P. L., Izzo A., Hill M., Drucker D. J. Intestinal function in mice with small bowel growth induced by glucagon- like peptide-2. Am. J. Physiol. 272:1997;E1050.
13. Cheeseman C. I. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. Am. J. Physiol. 273:1997;R1965.
14. Kato Y., Yu D., Schwartz M. Z. Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo. J. Pediatr. Surg. 34:1999;18.
15. Scott R. B., Kirk D., MacNaughton W. K., Meddings J. B. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am. J. Physiol. 275:1998;G911.
16. Chance W. T., Foley-Nelson T., Thomas I., Balasubramaniam A. Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2. Am. J. Physiol. 273:1997;G559.
17. Drucker D. J., Yusta B., Boushey R. P., DeForest L., Brubaker P. L. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am. J. Physiol. 276:1999;G79.
18. Boushey R. P., Yusta B., Drucker D. J. Glucagon-like peptide-2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am. J. Physiol. 277:1999;E937.
19. Bernard N., MacNaughton W., Scott R., Kirk D., Meddings J. Glucagon-like peptide-2 (GLP-2) accelerates healing of indomethacin-induced enteritis. Gasteroenterology. 116:1999;A122.
20. Pritchard D., Potten C., Hickman J. The relationship between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracil-induced histopathology in murine intestinal epithelia. Cancer Res. 58:1998;5453.
21. Drucker D. J., Shi Q., Crivici A., Sumner-Smith M., Tavares W., Hill M., DeForest L., Cooper S., Brubaker P. L. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat. Biotechnol. 15:1997;673.
22. Drucker D. J., DeForest L., Brubaker P. L. Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. Am. J. Physiol. 273:1997;G1252.
23. Howarth G., Cool J., Bourne A., Ballard F., Read L. Insulin-like growth factor-I (IGF-1) stimulates growth of the damaged intestine in rats, when administered following, but not concurrent with methotrexate. Growth Factors. 15:1998;279.
24. Sonis S., Costa J., Evitts S., Lindquist L., Nicholson M. Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive chemotherapy. Oral Surg. Oral Med. Oral Pathol. 74:1992;749.
25. Roche A., Bognel J., Bernier J. Correlation between the histological changes and glucose intestinal absorption following a single dose of 5 fluorouracil. Digestion. 3:1970;195.
26. Gardner M., Samson R., Heading R. Changes in absorptive and peptide hydrolase activities in rat small intestine after administration of 5-fluorouracil. Clin. Sci. 54:1978;411.
27. Drucker D. J., Erlich P., Asa S. L., Brubaker P. L. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc. Natl. Acad. Sci. USA. 93:1996;7911.
28. Burholt D., Schenken L., Kovacs C., Hagmann R. Response of the murine gastrointestinal epithelium to cis-dichlorodiamineplatinum II: Radiation combination. Int. J. Radiat. Oncol. Biol. Phys. 5:1979;1377.
29. Galand P., Degraef C. Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labelling for making S phase cells in paraffin sections from animal and human tissues. Cell Tissue Kinet. 22:1989;383.
30. Kurki P., Vanderlaan M., Dolbeare F., Gray J., Tan E. Expression of proliferating cell neclear antigen (PCNA/cyclin) during the cell cycle. Exp. Cell Res. 166:1986;209.
31. Tranishi S., Kitade F., Itaya H. Effects of anticancer agents on the intestinal epithelium. Gastroenterol. Jpn. 11:1976;182.
32. Cunningham D., Morgan R., Mills P., Nelson L., Toner P., Soukop M., McArdle C., Russell R. Functional and structural changes of the human proximal small intestine after cytotoxic therapy. J. Clin. Pathol. 38:1985;265.
33. White R., Fuqua W., Barrett O. The effect of 5-fluorouracil on small bowel mucosa. J. Surg. Oncol. 3:1971;501.